by webmaster | Jan 16, 2024 | Biosimilars Week
The first blog post for this year was on interchangeability. In it I announced that SAHPRA has decided that biosimilars will be interchangeable with its reference products without requiring additional data to support such a claim. This decision followed that of the...
by webmaster | Jan 16, 2024 | Biosimilars Week
The approval of Rybelsus®, which contains the GLP-1 agonist, semaglutide, by the EMA in April 20201 is of special interest because, unlike other biologics that are mostly parenterally administered, it was formulated as an immediate release tablet for oral...
by webmaster | Nov 8, 2023 | Biosimilars Week
The approval of Rybelsus®, which contains the GLP-1 agonist, semaglutide, by the EMA in April 20201 is of special interest because, unlike other biologics that are mostly parenterally administered, it was formulated as an immediate release tablet for oral...
by webmaster | Oct 29, 2021 | Biosimilars Week
We want to hear from you! This #GlobalBiosimilarsWeek, share your stories, information and educational resources, and initiatives so we can build a better world for biosimilars— together. Join the movement — be the voice of #biosimilars!...
by webmaster | Oct 29, 2021 | Biosimilars Week
Greater access to #biosimilar = more care for more patients. https://bit.ly/GlobalBiosimilarsWeek #GlobalBiosimilarsWeek #Biosimilars are the key to building a better future for patients around the globe. In order to provide more patients with more care, we need...
by webmaster | Oct 29, 2021 | Biosimilars Week
With the lower treatment costs achieved thanks to #biosimilars, we can re-invest in other health care services – like childcare, eldercare, mental health services, research and more. #GlobalBiosimilarsWeek Biosimilars treatment costs for patients, government...
